Adrenocortical carcinoma

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 13:18, 25 January 2018 by Dryang (talk | contribs) (Text replacement - "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:300%"> Just 8 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br>  '''Link:''' http://j.mp/2BlBaoQ </span> |}" to "{{:Editing test page 2}}")
Jump to navigation Jump to search

Carboplatin & Paclitaxel (CP)

CP: Carboplatin & Paclitaxel

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Forde et al. 2022 (CheckMate 816) 2017-2019 Phase 3 (C) 1a. CP & Nivolumab
1b. CVb & Nivolumab
1c. DC & Nivolumab 		Inferior EFS

Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details. This study was conducted in the United States. The reason for the study was that an unanswered question at the time was whether adding an immune checkpoint inhibitor would improve outcomes.

Biomarker eligibility criteria

  • CheckMate 816: No sensitizing EGFR or ALK mutations

Chemotherapy

21-day cycle for 3 cycles

Subsequent treatment

References

  1. CheckMate 816: Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. Epub 2022 Apr 11. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02998528

Start of hidden/commented information for virtual editor End of hidden/commented information for virtual editor



Start of comment inserted by visual editor(edited again by visual editor)

(edited again by visual editor end)End of comment inserted by visual editor
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

7 regimens on this page
10 variants on this page


Guidelines

NCCN

Adjuvant therapy

Mitotane monotherapy

back to top

There is limited and controversial clinical trial information about adjuvant mitotane use. See the references for additional case series and expert recommendation articles.

Regimen #1

Study Evidence
Wängberg et al. 2010 Phase II

Patients started on adjuvant mitotane within 4 weeks of their surgical resection.

Chemotherapy

  • Mitotane (Lysodren) 2000 mg PO per day (frequency not specified, such as whether the total daily dose was divided into a few doses throughout the day); within the first 2 to 3 months, dose was adjusted to achieve a target therapeutic drug level of 14 to 20 mg/L

2 to 3-year course

Regimen #2

Study Evidence
Haak et al. 1994 Phase II

Haak et al. 1994 concluded that "mitotane treatment in adrenocortical carcinoma is effective only when high serum levels [trough of at least 14 mg/L] can be achieved."

Chemotherapy

  • Mitotane (Lysodren) 1000 to 2000 mg PO QID (total dose per day: 4000 to 8000 mg), with target mitotane trough of above 14 mg/L

Supportive medications

2-year course "if resection was judged to be complete or for 1 year after apparent disappearance of the tumour"

References

  1. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1993 May 15;71(10):3119-23. link to original article PubMed
  2. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994 May;69(5):947-51. contains verified protocol link to PMC article PubMed content property of HemOnc.org
  3. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007 Jun 7;356(23):2372-80. link to original article PubMed
  4. Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009 Sep 20;27(27):4619-29. Epub 2009 Aug 10. link to original article link to PMC article PubMed
  5. Wängberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Odén A, Ahlman H. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer. 2010 Feb 18;17(1):265-72. Print 2010 Mar. link to original article contains verified protocol PubMed

Mitotane & Streptozocin

back to top

Regimen

Study Evidence
Khan et al. 2010 Phase II

Induction course

5-day course, followed by main regimen

Main regimen

Supportive medications

21-day cycles; duration of therapy not clearly specified

References

  1. Khan TS, Imam H, Juhlin C, Skogseid B, Gröndal S, Tibblin S, Wilander E, Oberg K, Eriksson B. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000 Oct;11(10):1281-7. link to original article contains verified protocol PubMed

Recurrent, locally advanced, or metastatic disease

Mitotane monotherapy

back to top

Regimen

Study Evidence
Veytsman et al. 2009 Review

Chemotherapy

  • Mitotane (Lysodren) 1000 to 2000 mg PO per day (frequency not specified), then increase dose by 1000 to 2000 mg every 1 to 2 weeks to the maximum tolerated dose, not to exceed 6000 mg ("never greater than 6 to 10 g/d").
    • Target mitotane drug level is 10 to 14 mg/L.

References

  1. Review: Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009 Sep 20;27(27):4619-29. Epub 2009 Aug 10. link to original article contains verified protocol link to PMC article PubMed

Mitotane & EDP

back to top

EDP: Etoposide, Doxorubicin, Platinol (Cisplatin)

Regimen #1

Study Evidence Comparator Efficacy
Fassnacht et al. 2012 (FIRM-ACT) Phase III Mitotane & Streptozocin Superior PFS

Mitotane is started at least 1 week before the other chemotherapy; the rest of the therapy is as described below.

Chemotherapy

Supportive medications

  • Glucocorticoid replacement was recommended in all patients except those with persistent Cushing's syndrome.

28-day cycles

Regimen #2

Study Evidence
Berruti et al. 2005 Phase II

Chemotherapy

  • Mitotane (Lysodren) 1000 mg PO per day (frequency not specified, such as whether the total daily dose was divided into a few doses throughout the day) on days 1 to 28; then dose is increased as tolerated up to 4000 mg/day or maximum tolerated dose
  • Etoposide (Vepesid) 100 mg/m2 IV once per day on days 5 to 7
  • Doxorubicin (Adriamycin) 20 mg/m2 IV once per day on days 1 & 8
  • Cisplatin (Platinol) 40 mg/m2 IV once per day on days 2 & 9

28-day cycle for up to 6 cycles

References

  1. Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A, Dogliotti L. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005 Sep;12(3):657-66. link to original article contains verified protocol PubMed
  2. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97. Epub 2012 May 2. link to original article contains verified protocol PubMed

Mitotane & Streptozocin

back to top

Regimen

Study Evidence Comparator Efficacy
Fassnacht et al. 2012 (FIRM-ACT) Phase III Mitotane & EDP Inferior PFS

Mitotane is started at least 1 week before the other chemotherapy; the rest of the therapy is as described below.

Chemotherapy

  • Mitotane (Lysodren) PO on days 1 to 21 (initial dose and frequency not specified)
    • Target mitotane trough of 14 to 20 mg/L
  • Streptozocin (Zanosar) as follows:
    • Cycle 1: 1000 mg IV once per day on days 1 to 5
    • Cycle 2 onwards: 2000 mg IV once on day 1

Supportive medications

  • Glucocorticoid replacement was recommended in all patients except those with persistent Cushing's syndrome.

21-day cycles

References

  1. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97. Epub 2012 May 2. link to original article contains verified protocol PubMed

Placebo

back to top

Regimen

Study Evidence Comparator Efficacy
Fassnacht et al. 2015 Phase III (C) Linsitinib Seems not superior

No active antineoplastic treatment.

References

  1. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Adrenocortical_carcinoma&oldid=23592"